TW337488B - A carbohydrate glass matrix for the sustained release of a therapeutic agent - Google Patents

A carbohydrate glass matrix for the sustained release of a therapeutic agent

Info

Publication number
TW337488B
TW337488B TW081108933A TW81108933A TW337488B TW 337488 B TW337488 B TW 337488B TW 081108933 A TW081108933 A TW 081108933A TW 81108933 A TW81108933 A TW 81108933A TW 337488 B TW337488 B TW 337488B
Authority
TW
Taiwan
Prior art keywords
therapeutic agent
glass matrix
carbohydrate
sustained release
compound
Prior art date
Application number
TW081108933A
Other languages
English (en)
Inventor
N Raman Siva
P Cunningham John
Original Assignee
Pitman Moore Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25184119&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW337488(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pitman Moore Inc filed Critical Pitman Moore Inc
Application granted granted Critical
Publication of TW337488B publication Critical patent/TW337488B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW081108933A 1991-12-05 1992-11-09 A carbohydrate glass matrix for the sustained release of a therapeutic agent TW337488B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80258191A 1991-12-05 1991-12-05

Publications (1)

Publication Number Publication Date
TW337488B true TW337488B (en) 1998-08-01

Family

ID=25184119

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081108933A TW337488B (en) 1991-12-05 1992-11-09 A carbohydrate glass matrix for the sustained release of a therapeutic agent

Country Status (11)

Country Link
US (1) US5356635A (zh)
EP (1) EP0615438B1 (zh)
CN (1) CN1065439C (zh)
AT (1) ATE140620T1 (zh)
AU (1) AU3125193A (zh)
CA (1) CA2125148C (zh)
DE (1) DE69212497T2 (zh)
DK (1) DK0615438T3 (zh)
ES (1) ES2090714T3 (zh)
TW (1) TW337488B (zh)
WO (1) WO1993010758A1 (zh)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT748213E (pt) 1994-03-07 2004-08-31 Nektar Therapeutics Metodos e composicoes para administracao pulmonar de insulina
US5817327A (en) * 1994-07-27 1998-10-06 The Trustees Of The University Of Pennsylvania Incorporation of biologically active molecules into bioactive glasses
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6586006B2 (en) * 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
WO1996003978A1 (en) * 1994-08-04 1996-02-15 Quadrant Holdings Cambridge Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
AU3570495A (en) 1994-09-22 1996-04-09 Quadrant Holdings Cambridge Limited Compositions for use in rehydration and nutrition during athletic exercise and methods of making same
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6964771B1 (en) 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
MX9709716A (es) * 1995-06-07 1998-03-31 Quadrant Holdings Cambridge Metodos para incorporar substancias estables dentro de matrices de vidrio celular secas y composiciones obtenidas mediante los mismos.
US5958455A (en) * 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
ES2325046T3 (es) 1996-06-26 2009-08-24 The Board Of Regents, The University Of Texas System Formulacion farmaceutica extruible por fusion en caliente.
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
US6149939A (en) * 1997-05-09 2000-11-21 Strumor; Mathew A. Healthful dissolvable oral tablets, and mini-bars
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6352722B1 (en) 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
CA2317411C (en) 1998-01-30 2005-06-28 Scios Inc. Controlled release delivery of peptide or protein
KR19990071255A (ko) * 1998-02-28 1999-09-15 성재갑 소마토트로핀과 비타민의 합제 조성물
US6835194B2 (en) 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6541021B1 (en) 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
ATE244558T1 (de) 1999-04-16 2003-07-15 Novo Nordisk As Trockene formbare arzneistoffformulierung
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6207193B1 (en) * 1999-12-27 2001-03-27 Stephen E. Feldman Transdermal drug delivery system
KR20090007504A (ko) 2000-02-24 2009-01-16 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
AU2001249214A1 (en) 2000-03-15 2001-09-24 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU2001271491A1 (en) 2000-06-26 2002-01-08 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) * 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
EP1313425B1 (en) * 2000-07-14 2007-03-07 Novo Nordisk A/S Method of moulding a pharmaceutical composition in a packaging material
GB0124710D0 (en) * 2001-10-15 2001-12-05 Quadrant Healthcare Uk Ltd Therapeutic composition
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
EP2218448B1 (en) 2002-12-13 2015-09-23 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
CA2575988C (en) 2004-08-04 2014-02-18 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
CA2581287C (en) 2004-09-17 2015-08-25 Durect Corporation Sustained local anesthetic composition containing bupivacaine and saib
US8691772B2 (en) 2005-01-04 2014-04-08 Yeda Research And Development Co. Ltd. HSP60, HSP60 peptides and T cell vaccines for immunomodulation
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2006109312A2 (en) * 2005-04-15 2006-10-19 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
AU2006268088B2 (en) * 2005-07-12 2011-05-12 Renovo Ltd Pharmaceutical compositions comprising a TGF-beta superfamily member
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
GB2430880A (en) * 2005-10-04 2007-04-11 Cambridge Biostability Ltd Pharmaceutical compositions stabilized in glassy particles
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
JP2011506319A (ja) 2007-12-06 2011-03-03 デュレクト コーポレーション 疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
WO2009111649A2 (en) 2008-03-05 2009-09-11 Regenerative Research Foundation Methods and compositions for delivery of exogenous factors to nervous system sites
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
RU2567723C2 (ru) 2009-07-22 2015-11-10 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
EA201290541A1 (ru) 2009-12-21 2013-05-30 Амбркс, Инк. Модифицированные бычьи соматотропиновые полипептиды и их применение
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
US8481308B2 (en) 2010-07-01 2013-07-09 Regenerative Research Foundation Methods for culturing undifferentiated cells using sustained release compositions
PE20131126A1 (es) 2010-09-02 2013-10-21 Gruenenthal Chemie Forma de dosificacion resistente a alteracion que comprende un polimero anionico
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
DK2736497T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
WO2013156453A1 (en) 2012-04-18 2013-10-24 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CA2907950A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (ja) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エタノール過量放出に対して防護されている多粒子
WO2016079330A1 (en) * 2014-11-21 2016-05-26 Technical University Of Denmark Gel formulations for local drug release
KR20170139158A (ko) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
US10758567B2 (en) * 2015-09-16 2020-09-01 Immune Ventures LLC In vivo priming of natural killer cells
AU2017266410B2 (en) * 2016-05-20 2022-07-14 Nanovi Radiotherapy Aps Palpable marker composition
EP3630201A1 (en) * 2017-05-24 2020-04-08 Technical University of Denmark Development of injectable fiducial markers for image guided radiotherapy with dual mri and ct visibility
BR112022013784A2 (pt) 2020-01-13 2022-10-11 Durect Corp Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2413419A (en) * 1943-02-27 1946-12-31 Searle & Co Pellet for administering gonadotropic pituitary hormones
US2918411A (en) * 1957-11-01 1959-12-22 Olin Mathieson Pharmaceutical preparations
FR2383659A1 (fr) * 1977-03-16 1978-10-13 Berri Balzac Procede de preparation de comprimes contenant des substances labiles en microdispersion
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
US5266333A (en) * 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US4765980A (en) * 1986-04-28 1988-08-23 International Minerals & Chemical Corp. Stabilized porcine growth hormone
US4857506A (en) * 1987-01-12 1989-08-15 American Cyanamid Company Sustained release growth hormone compositions for parenteral administration and their use
JP2821925B2 (ja) * 1987-11-16 1998-11-05 バクスター、インターナショナル、インコーポレイテッド 有益な剤の制御された投与のためのガラス状マトリックス
EP0345628B1 (en) * 1988-06-07 1993-05-12 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5219572A (en) * 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins

Also Published As

Publication number Publication date
WO1993010758A1 (en) 1993-06-10
ATE140620T1 (de) 1996-08-15
CN1065439C (zh) 2001-05-09
EP0615438B1 (en) 1996-07-24
DE69212497T2 (de) 1996-12-12
CN1072861A (zh) 1993-06-09
US5356635A (en) 1994-10-18
ES2090714T3 (es) 1996-10-16
CA2125148C (en) 1999-05-11
DE69212497D1 (de) 1996-08-29
AU3125193A (en) 1993-06-28
DK0615438T3 (da) 1996-11-11
CA2125148A1 (en) 1993-06-10
EP0615438A1 (en) 1994-09-21

Similar Documents

Publication Publication Date Title
TW337488B (en) A carbohydrate glass matrix for the sustained release of a therapeutic agent
ES2159591T3 (es) Composicion de liberacion controlada.
HU9201719D0 (en) Preparations with elogated effect
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
MY113488A (en) Compounds with growth hormone releasing properties
AU7702291A (en) Dietary fiber, its process and physiologically active composition containing the same as an active ingredient
GR3004752T3 (zh)
AU4297089A (en) Dispersable formulation of diclofenac in free acid form
HU9201254D0 (en) Rapamicine-carbamates and medical preparations containing them as active agents
AU625083B2 (en) Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)- en-20-yn-3-one
SE8804628A (zh)
ZA948162B (en) Dihaiopropene compound, insecticide/acaricide, containing said dihalopropene compound as active ingredient, and intermediate compound for use in production of said dihalopropene compound.
IL105942A0 (en) Biologically active eburnamenine derivatives,their preparation and pharmaceutical compositions containing them
AU3318389A (en) Azelastine-containing medicaments with controlled release of the active substance
AU5980590A (en) 5-substituted 1,3,4-thiadizole derivatives, their preparation and their use as pesticides
AU591046B2 (en) Physiologically active agent for agricultural use
DE3872808D1 (de) Pyrazolderivat und insektizide und mitizide zusammenstellung, das derivat als aktives agens enthaltend.
IL81857A (en) Insecticidal compositions for controlling scarabid larvae,containing bacterial spored of milky disease bacillus free of sporangia,and in vitro method for producing such spores
NZ324674A (en) Rapid release tablet comprising tolfenamic acid, alginic acid and a superdisintegrant
HUT63306A (en) Insecticidal compositions comprising guanide derivatives as active ingredient and process for producing the active ingredient
HU9201358D0 (en) 2-amino-pirimidine-4-carboxamide derivatives, process for their production and for the production of medical preparations containing them as active agents
ZA924242B (en) Re-formulated diamox sustets
AU3200393A (en) Body tissue omega-3 fatty-acid-augmenting agent and nutrient composition containing the same
DE3271647D1 (en) Polymeric diffusion matrix containing propranolol
AU2230092A (en) Insecticidal and acaricidal plant-protection agents containing substituted 1,2,4-oxadiazole derivatives